CRISTINA R. G.
- Country
- Spain
- Department
- Gastroenterology (inflammatory bowel disease section)
Research Overview
- Phase 3b, Randomized, Open‑Label, Active‑Controlled Trial Comparing Guselkumab Versus Risankizumab for Efficacy and Safety in Moderately to Severely Active Crohn’s Disease
- Efficacy and Safety of Upadacitinib in Maintenance and Long-Term Extension for Crohn's Disease Post-Induction Responders
- Evaluation of Guselkumab and Golimumab Combination Therapy Efficacy and Safety in Moderate to Severe Ulcerative Colitis: A Phase 2b Randomized Controlled Trial
Data & Insights
Has run more than one trial at 143 of 326 partner sites.
Specializations
Inflammatory Bowel Disease Management
This investigator specializes in treating complex inflammatory bowel diseases, with particular emphasis on both Crohn's Disease and Ulcerative Colitis.
- Moderate to Severe Disease States
- Long-term Disease Management
- Maintenance Therapy Approaches
Their work encompasses comprehensive disease management strategies for patients with varying severity levels of inflammatory bowel conditions.
Advanced Therapeutic Applications
The investigator focuses on evaluating innovative biological therapies and targeted treatments for gastrointestinal disorders.
- Combination Therapy Approaches
- Novel Therapeutic Agents
- Biosimilar Evaluations
Their expertise extends to assessing both established and emerging therapeutic options for inflammatory bowel conditions.
Clinical Outcomes Assessment
The investigator specializes in evaluating treatment efficacy and safety profiles in gastrointestinal medicine.
- Disease Activity Monitoring
- Safety Assessment Protocols
- Long-term Therapeutic Outcomes
Their work involves comprehensive assessment of clinical responses and treatment effectiveness in inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.